{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:38Z","timestamp":1740144158645,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40273-022-01209-8","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T04:02:34Z","timestamp":1666843354000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"41","author":[{"given":"Ben","family":"Wijnen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1007-4284","authenticated-orcid":false,"given":"Willem","family":"Witlox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Fayter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Otten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Posadzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gill","family":"Worthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Stirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos","family":"Kleijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Joore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"1209_CR1","volume-title":"Fenfluramine for treating Dravet syndrome: a Single Technology Assessment","author":"D Fayter","year":"2020","unstructured":"Fayter D, Wijnen B, Ramaekers BLT, Otten T, Witlox W, Ryder S, et al. Fenfluramine for treating Dravet syndrome: a Single Technology Assessment. York: Kleijnen Systematic Reviews Ltd.; 2020."},{"key":"1209_CR2","unstructured":"National Institute for Health and Care Excellence. Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]. Final appraisal determination committe papers [Internet]. London: National Institute for Health and Clinical Excellence, 2022. 171p. https:\/\/www.nice.org.uk\/guidance\/ta808\/evidence\/final-appraisal-determination-committee-papers-pdf-11134456957. Accessed 1 Sep 2022."},{"key":"1209_CR3","doi-asserted-by":"crossref","unstructured":"National Institute for Health and Care Excellence. Fenfluramine for treating seizures associated with Dravet syndrome: Technology appraisal guidance [TA808] [Internet]. London: NICE, 2022. https:\/\/www.nice.org.uk\/guidance\/ta808. Accessed 19 Sep 2022.","DOI":"10.1136\/heartjnl-2022-321095"},{"key":"1209_CR4","unstructured":"National Institute for Health and Care Excellence. Fenfluramine for treating Dravet syndrome [ID1109]. Final scope [Internet]. London: National Institute for Health and Clinical Excellence, 2020. 4p. https:\/\/www.nice.org.uk\/guidance\/gid-ta10373\/documents\/final-scope-2. Accessed 11 Aug 2020."},{"key":"1209_CR5","unstructured":"Zogenix International Ltd. Fenfluramine for treating Dravet syndrome [ID1109]: Submission to National Institute of Health and Care Excellence. Single technology appraisal (STA): Document B - Company evidence submission: Zogenix International Ltd., 2020. 182p."},{"key":"1209_CR6","unstructured":"Zogenix International Ltd. Fenfluramine for treating Dravet syndrome [ID1109]: Submission to National Institute of Health and Care Excellence. Single technology appraisal (STA): Appendices C-N: Zogenix International Ltd., 2020. 98p."},{"key":"1209_CR7","unstructured":"European Medicines Agency. Fintepla (fenfluramine): Authorisation details [Internet]. Amsterdam: EMA. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fintepla#authorisation-details-section. Accessed 19 Sep 2022."},{"key":"1209_CR8","unstructured":"Zogenix International Ltd. Fenfluramine for treating Dravet syndrome [ID1109]: Response to request for clarification from the ERG: Zogenix International Ltd., 2020. 97p."},{"key":"1209_CR9","unstructured":"Dravet Syndrome UK. About Dravet syndrome: treatments and outcomes [Internet]. https:\/\/www.dravet.org.uk\/about-dravet-syndrome\/treatments-and-outcomes\/. Accessed 7 Oct 2020."},{"key":"1209_CR10","unstructured":"National Institute for Health and Care Excellence. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome. Technology appraisal guidance [TA614]. Final Appraisal Determination [Internet]. London: NICE, 2019. https:\/\/www.nice.org.uk\/guidance\/ta614"},{"key":"1209_CR11","volume-title":"Fenfluramine for treating Dravet syndrome [ID1109]: Clarification letter","author":"National Institute for Health and Care Excellence","year":"2020","unstructured":"National Institute for Health and Care Excellence. Fenfluramine for treating Dravet syndrome [ID1109]: Clarification letter. London: NICE; 2020."},{"issue":"10216","key":"1209_CR12","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243\u201354.","journal-title":"Lancet"},{"key":"1209_CR13","unstructured":"Zogenix International Ltd. Study 1 CSR; August 2019 CONFIDENTIAL, 2019."},{"issue":"3","key":"1209_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","volume":"77","author":"R Nabbout","year":"2020","unstructured":"Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300\u20138.","journal-title":"JAMA Neurol"},{"key":"1209_CR15","unstructured":"Zogenix International Ltd. Study 1504 CSR; December 2018 CONFIDENTIAL, 2018."},{"key":"1209_CR16","unstructured":"Zogenix International Ltd. Study 1503 Interim CSR; 21 December 2018 CONFIDENTIAL, 2018."},{"issue":"7","key":"1209_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/epi.13407","volume":"57","author":"B Ceulemans","year":"2016","unstructured":"Ceulemans B, Schoonjans A-S, Marchau F, et al. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57(7):129\u201334.","journal-title":"Epilepsia"},{"issue":"2","key":"1209_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ene.13195","volume":"24","author":"A Schoonjans","year":"2017","unstructured":"Schoonjans A, Paelinck BP, Marchau F, Gunning B, Gammaitoni A, Galer BS, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017;24(2):309\u201314.","journal-title":"Eur J Neurol"},{"issue":"7","key":"1209_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","volume":"53","author":"B Ceulemans","year":"2012","unstructured":"Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131\u20139.","journal-title":"Epilepsia"},{"issue":"7","key":"1209_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMc1708349","volume":"377","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;377(7):699\u2013700.","journal-title":"N Engl J Med"},{"issue":"5","key":"1209_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","volume":"77","author":"I Miller","year":"2020","unstructured":"Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(5):613\u201321.","journal-title":"JAMA Neurol"},{"issue":"7","key":"1209_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40273-014-0153-y","volume":"32","author":"KA Khan","year":"2014","unstructured":"Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE. Mapping EQ-5D utility scores from the PedsQL\u2122 generic core scales. Pharmacoeconomics. 2014;32(7):693\u2013706.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1209_CR23","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health."},{"key":"1209_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fneur.2020.00829","volume":"11","author":"G D'Onofrio","year":"2020","unstructured":"D\u2019Onofrio G, Kuchenbuch M, Hachon-Le Camus C, Desnous B, Staath V, Napuri S, et al. Slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study. Front Neurol. 2020;11:829.","journal-title":"Front Neurol"},{"key":"1209_CR25","unstructured":"Desai I, Hassan E, Soponski R, Tan HJ. UK Northwest profile of epidyolex use for refractory seizures in children. In, 2021."},{"key":"1209_CR26","unstructured":"Scheffer IE, Devinsky O, Perry S, Wheless J, Thiele EA, Wirrell E, et al. Efficacy and tolerability of adjunctive FINTEPLA (fenfluramine hydrochloride) in an open-label extension study of Dravet syndrome patients treated for up to 3 years. Presented at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual, April 12-16, 2021."},{"issue":"10","key":"1209_CR27","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/epi.17036","volume":"62","author":"IE Scheffer","year":"2021","unstructured":"Scheffer IE, Halford JJ, Miller I, Nabbout R, Sanchez-Carpintero R, Shiloh-Malawsky Y, et al. Add-on cannabidiol in patients with Dravet syndrome: results of a long-term open-label extension trial. Epilepsia. 2021;62(10):2505\u201317.","journal-title":"Epilepsia"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01209-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01209-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01209-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T05:02:04Z","timestamp":1678424524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01209-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01209-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"6 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correct Open Access funding information has been updated in the Funding Note.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme. See the HTA programme website for further project information (). This summary of the ERG report was compiled after NICE issued the FAD. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NICE or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}